Literature DB >> 30150255

Screening for Th17-Dependent Pneumococcal Vaccine Antigens: Comparison of Murine and Human Cellular Immune Responses.

Adam Finn1,2, Richard Malley3, Ying-Jie Lu4, Elizabeth Oliver1, Fan Zhang3, Caroline Pope1.   

Abstract

Conjugate vaccines against Streptococcus pneumoniae have significantly reduced the incidence of diseases caused by the serotypes included in those vaccines; however, there is still a need for vaccines that confer serotype-independent protection. In the current study, we have constructed a library of conserved surface proteins from S. pneumoniae and have screened for IL-17A and IL-22 production in human immune cells obtained from adenoidal/tonsillar tissues of children and IL-17A production in splenocytes from mice that had been immunized with a killed whole-cell vaccine or previously exposed to pneumococcus. A positive correlation was found between the rankings of proteins from human IL-17A and IL-22 screens, but not between those from human and mouse screens. All proteins were tested for protection against colonization, and we identified protective antigens that are IL-17A dependent. We found that the likelihood of finding a protective antigen is significantly higher for groups of proteins ranked in the top 50% of all three screens than for groups of proteins ranked in the bottom 50% of all three. The results thus confirmed the value of such screens for identifying Th17 antigens. Further, these experiments have evaluated and compared the breadth of human and mouse Th17 responses to pneumococcal colonization and have enabled the identification of potential vaccine candidates based on immunological responses in mouse and human cells.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Streptococcus pneumoniae; Th17; antigen discovery; colonization

Mesh:

Substances:

Year:  2018        PMID: 30150255      PMCID: PMC6204694          DOI: 10.1128/IAI.00490-18

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  The Gene Polymorphism of IL-17 G-152A is Associated with Increased Colonization of Streptococcus pneumoniae in Young Finnish Children.

Authors:  Juho Vuononvirta; Ville Peltola; Jorma Ilonen; Jussi Mertsola; Qiushui He
Journal:  Pediatr Infect Dis J       Date:  2015-09       Impact factor: 2.129

4.  GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.

Authors:  Ying-Jie Lu; Luciana Leite; Viviane Maimoni Gonçalves; Waldely de Oliveira Dias; Celia Liberman; Fernando Fratelli; Mark Alderson; Andrea Tate; Jean-François Maisonneuve; George Robertson; Rita Graca; Sabina Sayeed; Claudette M Thompson; Porter Anderson; Richard Malley
Journal:  Vaccine       Date:  2010-09-19       Impact factor: 3.641

5.  Bacterial lipoproteins differentially regulate human primary and memory CD4+ T and B cell responses to pneumococcal protein antigens through Toll-like receptor 2.

Authors:  Qibo Zhang; Linda Bagrade; Ed Clarke; James C Paton; Desmond A Nunez; Adam Finn
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

6.  Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.

Authors:  Fabrice Godfroid; Philippe Hermand; Vincent Verlant; Philippe Denoël; Jan T Poolman
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

7.  Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.

Authors:  Aderonke Odutola; Martin O C Ota; Martin Antonio; Ezra O Ogundare; Yauba Saidu; Ebenezer Foster-Nyarko; Patrick K Owiafe; Fatima Ceesay; Archibald Worwui; Olubukola T Idoko; Olumuyiwa Owolabi; Abdoulie Bojang; Sheikh Jarju; Isatou Drammeh; Beate Kampmann; Brian M Greenwood; Mark Alderson; Magali Traskine; Nathalie Devos; Sonia Schoonbroodt; Kristien Swinnen; Vincent Verlant; Kurt Dobbelaere; Dorota Borys
Journal:  Vaccine       Date:  2017-04-04       Impact factor: 3.641

8.  Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage.

Authors:  Adam K A Wright; Daniela M Ferreira; Jenna F Gritzfeld; Angela D Wright; Kathryn Armitage; Kondwani C Jambo; Emily Bate; Sherouk El Batrawy; Andrea Collins; Stephen B Gordon
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

9.  Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine.

Authors:  Kristin L Moffitt; Richard Malley; Ying-Jie Lu
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

10.  Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung.

Authors:  Adam K A Wright; Mathieu Bangert; Jenna F Gritzfeld; Daniela M Ferreira; Kondwani C Jambo; Angela D Wright; Andrea M Collins; Stephen B Gordon
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

View more
  4 in total

1.  Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice.

Authors:  Mohammad Omar Faruk Shaikh; Matthew M Schaefers; Christina Merakou; Marco DiBlasi; Sarah Bonney; Tiffany Liao; David Zurakowski; Margaret Kehl; David E Tabor; Antonio DiGiandomenico; Gregory P Priebe
Journal:  Infect Immun       Date:  2022-09-07       Impact factor: 3.609

2.  Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection.

Authors:  Sudeep Kumar; Raju Sunagar; Edmund J Gosselin
Journal:  Vaccines (Basel)       Date:  2020-04-23

3.  Generation of protective pneumococcal-specific nasal resident memory CD4+ T cells via parenteral immunization.

Authors:  Richard Malley; Bruce H Horwitz; Joanne M O'Hara; Naresh S Redhu; Elaine Cheung; Nahid G Robertson; Izabel Patik; Shorouk El Sayed; Claudette M Thompson; Muriel Herd; Katherine B Lucas; Evan Conaway; Cynthia C Morton; Donna L Farber
Journal:  Mucosal Immunol       Date:  2019-10-28       Impact factor: 7.313

4.  Exploring metal availability in the natural niche of Streptococcus pneumoniae to discover potential vaccine antigens.

Authors:  Lucille F van Beek; Kristin Surmann; H Bart van den Berg van Saparoea; Diane Houben; Wouter S P Jong; Christian Hentschker; Thomas H A Ederveen; Elena Mitsi; Daniela M Ferreira; Fred van Opzeeland; Christa E van der Gaast-de Jongh; Irma Joosten; Uwe Völker; Frank Schmidt; Joen Luirink; Dimitri A Diavatopoulos; Marien I de Jonge
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.